Kolexia
Lebbe Celeste Dermatologie
Lebbe Celeste
Dermatologie
Hôpital Saint-Louis
Paris, France
900 Activités
9 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Mélanome Tumeurs cutanées Carcinomes Métastase tumorale Sarcomes Carcinome à cellules de Merkel Sarcome de Kaposi Carcinome épidermoïde Tumeurs du cerveau

Collaborateurs

Voir plus
Mortier Laurent
Mortier Laurent
Hôpital Huriez, Lille, France
Grob Jean-Jacques
Grob Jean-Jacques
Hôpital La Timone, Marseille, France
Robert Caroline
Robert Caroline
Gustave-Roussy, Villejuif, France
Baroudjian Barouyr
Baroudjian Barouyr
Hôpital Saint-Louis, Paris, France

Industries

Voir plus
BMS
38 collaboration(s)
Dernière en 2023
Novartis
26 collaboration(s)
Dernière en 2023
Sanofi
22 collaboration(s)
Dernière en 2023
Pierre Fabre
17 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Line-field confocal optical coherence tomography (LC-OCT) features of a melanotic macule of the lip
EJC Skin Cancer   01 décembre 2024
European consensus-based interdisciplinary guideline for diagnosis, treatment and prevention of actinic keratoses, epithelial UV-induced dysplasia and field cancerization on behalf of European Association of Dermato-Oncology, European Dermatology Forum, European Academy of Dermatology and Venereology and Union of Medical Specialists (Union Européenne des Médecins Spécialistes).
Journal of the European Academy of Dermatology and Venereology : JEADV   07 mars 2024
RELATIVITY-127: A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination Versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants With Previously Untreated Metastatic or Unresectable Melanoma
Essai Clinique (BMS)   29 février 2024
A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors: A Phase Ib/II, Multicenter, Open-label, Dose Escalation Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF V600 - Dependent Advanced Solid Tumors
Essai Clinique (Pfizer)   15 février 2024
Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma: Phase 1b/2, Multicenter, Open-label Trial to Evaluate the Safety and Efficacy of Talimogene Laherparepvec and Ipilimumab Compared to Ipilimumab Alone in Subjects With Unresected, Stage IIIB-IV Melanoma
Essai Clinique (Amgen)   15 février 2024
Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200): A Phase II, Open-Label, Multicenter Trial to Investigate the Clinical Activity and Safety of Avelumab (MSB0010718C) in Subjects With Merkel Cell Carcinoma
Essai Clinique (Emd Serono)   14 février 2024
Pan Tumor Nivolumab Rollover Study: Pan-Tumor Study for Long Term Follow-up of Cancer Survivors Who Have Participated in Trials Investigating Nivolumab
Essai Clinique (BMS)   14 février 2024
A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).: A Phase 1/2 Study of ANV419 as Monotherapy or in Combination With Anti-PD-1 or Anti-CTLA-4 Antibody Following Anti-PD-1/Anti-PD-L1 Antibody Treatment in Patients With Unresectable or Metastatic Cutaneous Melanoma (OMNIA-1)
Essai Clinique (Anaveon AG)   09 février 2024
Clinical benefit of anti-PD-(L)1 immunotherapies in advanced cancer in France: a population-based estimate from 2014 to 2021.
ESMO open   09 février 2024
The combination of ipilimumab and nivolumab is still not reimbursed for BRAF-mutated melanoma patients in France: An unacceptable medical situation that raises ethical concerns.
Annales de dermatologie et de venereologie   06 février 2024